Clinical Trials Logo

Clinical Trial Summary

This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05235516
Study type Interventional
Source Akeso
Contact Ting Liu, MD
Phone +86 (0760) 8987 3999
Email clinicaltrials@akesobio.com
Status Recruiting
Phase Phase 3
Start date June 21, 2022
Completion date May 2029

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Recruiting NCT05406856 - PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer N/A
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05462379 - Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. Phase 1/Phase 2
Not yet recruiting NCT05210270 - HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy Phase 1/Phase 2
Recruiting NCT05722288 - Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Phase 2
Recruiting NCT06378840 - the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
Recruiting NCT05701735 - Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer N/A
Recruiting NCT05975593 - MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Not yet recruiting NCT04789941 - How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix Phase 2